查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018960

肥胖症治疗市场：2026-2032年全球市场预测（依治疗方法、药物类别、给药途径、病患年龄层、分销管道和最终用户划分）

Obesity Treatment Market by Treatment Type, Drug Class, Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年肥胖症治疗市场价值 166.9 亿美元，预计到 2026 年将成长至 180.2 亿美元，复合年增长率为 8.45%，到 2032 年将达到 294.6 亿美元。

主要市场统计数据
基准年 2025 166.9亿美元
预计年份：2026年 180.2亿美元
预测年份 2032 294.6亿美元
复合年增长率 (%) 8.45%

明确了融合临床创新、系统性挑战和策略重点的方向，这些正在重塑肥胖症治疗的提供方式，并为相关人员。

肥胖症治疗处于临床创新、不断变化的患者期​​望和不断演进的医疗政策的交汇点，这需要细緻入微的策略思考。药物治疗，特别是肠促胰素疗法的进步，透过提供新的​​非手术选择，重塑了治疗模式，改变了治疗路径、患者转诊模式以及支付方的参与方式。同时，外科手术介入也在不断发展，采用微创技术和精细的手术全期护理，在临床病情严重且合併症较多的情况下，仍然发挥着持续的解剖学干预作用。

临床范式、交付模式和支付方期望的演变正在推动肥胖症治疗从孤立的干预措施向纵向的、全面的护理模式进行系统性转变。

肥胖症治疗领域正经历一场变革，其驱动力来自药物治疗的突破性进展、外科治疗的改进以及数位治疗方法的日趋成熟。在药物治疗方面，利用代谢和食慾调节路径的治疗方法已展现出显着的临床减重效果，并伴随广泛的心血管代谢获益，这促使临床医生和支付方重新评估治疗方案和顺序。这种转变正在加速整合内分泌学、基层医疗、行为医学和营养服务的多学科诊疗模式的发展，从而增加持续患者管理的接触点。

预计 2025 年的贸易政策调整将对营运、定价和准入产生多方面的影响，因此，采取积极主动的参与策略来加强供应链的韧性和偿还能力至关重要。

2025年若美国推出新的关税或调整贸易政策，将带来一系列累积影响，整个肥胖症治疗生态系统的相关人员必须评估并应对这些影响。对进口药品活性成分、给药装置或特殊医疗设备征收关税，将增加依赖全球供应链的製造商的投入成本。这些成本压力将波及整个分销管道，并可能影响药品标价、回扣策略以及与支付方和医疗服务提供者的谈判动态。价格上涨的转嫁程度将取决于合约结构和治疗领域的竞争强度。

从多维细分观点，将治疗方法、药理分类、给药途径、患者群体、分销管道和医疗保健环境与策略挑战联繫起来。

细分市场分析揭示了治疗方法、药理机制、给药途径、患者人口统计特征、分销管道和终端用户环境之间复杂的相互作用。这些因素各自对临床实务和商业策略产生独特的影响。根据治疗类型，该领域包括药物治疗和外科手术。药物治疗又可细分为非处方药和处方药，而外科手术则包括减重手术、胃绕道手术和腹腔镜手术。这些区分至关重要，因为每种途径都涉及不同的临床决策点、监管要求和患者教育需求，这些因素决定了从初次咨询到长期追踪的患者治疗过程中涉及的相关人员类型。

美洲、欧洲、中东和非洲以及亚太地区的监管、报销和文化趋势各不相同，因此需要针对每个地区制定量身定制的准入和证据策略。

区域趋势差异显着，因此在监管沟通、准入策略和伙伴关係建设方面需要采取差异化的方法。在美洲，北美监管流程依託于完善的临床试验基础设施和更成熟的支付方框架，能够快速引进週期疗效显着且报销机制与疗效相符的治疗方法。该地区的医疗保健系统也面临着巨大的未满足需求和人口多样性，这为整合式医疗模式和基于价值的合约创造了机会，从而将报销与可持续的临床获益挂钩。

能够将差异化的临床结果证据、整合的护理伙伴关係以及适应性强的商业和供应链能力结合起来的组织将获得竞争优势。

如今，竞争格局日益取决于企业能否展现差异化的临床疗效、优化服务交付和支持，并以令人信服的卫生经济学证据赢得支付方的认可。领先的生物製药研发公司正投资于疗效研究和患者支持项目，以解决用药依从性、治疗连续性和长期安全性监测等问题。同时，医疗设备和手术创新者正致力于改善手术全期照护路径，并强化促进復健的方案，以减少併发症和降低治疗总成本。製药公司与专科诊所和数位医疗服务提供者之间的伙伴关係正在兴起，成为将行为介入、远端监测和用药依从性支援整合到商业服务中的一种有效途径，从而提升支付方和病患的价值。

为了确保获得服务并加快推广，领导者需要加强其价值链，建立基于价值的证据，并透过实践和协作努力来扩展综合患者照护服务模式。

产业领导者应推动一系列协作倡议，协调临床证据的取得、供应链韧性以及与支付方的合作，以维持医疗服务的可及性并促进创新。首先，应实现采购管道多元化，投资本地製造和策略供应商合作，以减轻贸易政策中断的影响，并降低活性成分和一次性医疗设备等关键投入品的交货前置作业时间风险。除了供应侧措施外，还应优化库存，并在合约中加入条款，以便在地缘政治不确定性加剧时期保持灵活性。

透过采用多层次的调查方法，结合对关键相关人员的访谈、有针对性的二手资料和严格的检验，我们确保获得可操作且引人注目的见解。

本研究途径结合了多层次的调查方法，旨在从多元可靠的资讯来源获取资讯并进行检验。主要研究内容包括对临床医生、支付方、采购经理和患者权益倡导组织代表进行结构化访谈，以获取关于临床决策、报销限制和就医障碍的第一手观点。除访谈外，专家咨询小组还会进行主题检验和情境测试、策略性假设压力测试，并识别新出现的营运风险。

一份简明扼要、全面全面的报告，强调了透过整合临床证据、营运弹性和支付方合作来改善治疗效果和维持医疗服务可近性的策略必要性。

肥胖症治疗生态系统正处于转折点，临床创新、供应链现状和支付方期望相互交织，重新定义了治疗路径。积极将循证医学成果与切实可行的准入策略和稳健的运营计划相结合的相关人员，将在改善患者预后的同时，获得更大的价值。药物治疗进展与手术治疗的相互作用凸显了采用综合性跨学科方法的必要性，这种方法需要考虑患者的异质性和长期管理需求。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗方法分類的肥胖症治疗市场

  • 药物治疗
    • 非处方药
    • 处方药
  • 手术治疗
    • 减重手术
    • 胃绕道手术
    • 腹腔镜手术

第九章：肥胖症治疗市场：依药物类别划分

  • 食慾抑制剂
  • GLP-1受体促效剂
  • 脂肪酶抑制剂
  • 代谢加速器

第十章：肥胖症治疗市场：依给药途径划分

  • 口服
  • 肠外

第十一章：依患者年龄层分類的肥胖症治疗市场

  • 成人
  • 老年人
  • 儿童

第十二章 肥胖症治疗市场：依通路划分

  • 实体零售
  • 线上零售

第十三章 肥胖症治疗市场：依最终使用者划分

  • 医院和诊所
  • 专科诊所
  • 减重与健康中心

第十四章 肥胖症治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 肥胖症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 肥胖症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国肥胖症治疗市场

第十八章：中国肥胖症治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Apollo Endosurgery, Inc.
  • AstraZeneca PLC
  • Atkins Nutritionals, Inc.
  • BTL Aesthetics
  • CH Boehringer Sohn AG & Ko. KG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Herbalife Ltd.
  • Johnson & Johnson Services, Inc.
  • Kellogg Company
  • Medtronic PLC
  • Merck & Co.
  • Novo Nordisk A/S
  • NutriSystem, Inc.
  • Olympus Corporation
  • Pfizer, Inc.
  • ReShape Lifesciences, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Viking Therapeutics, Inc.
  • VIVUS LLC
  • Zealand Pharma A/S
Product Code: MRR-EC2E133E32E2

The Obesity Treatment Market was valued at USD 16.69 billion in 2025 and is projected to grow to USD 18.02 billion in 2026, with a CAGR of 8.45%, reaching USD 29.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.69 billion
Estimated Year [2026] USD 18.02 billion
Forecast Year [2032] USD 29.46 billion
CAGR (%) 8.45%

A clear orientation to the converging clinical innovations, system-level challenges, and strategic priorities that are reshaping obesity treatment delivery and stakeholder opportunity

Obesity treatment sits at the intersection of clinical innovation, shifting patient expectations, and evolving health policy, creating a landscape that demands nuanced strategic thinking. Advances in pharmacotherapy-most notably in incretin-based therapies-have reframed treatment paradigms by offering new non-surgical options that alter care pathways, patient referral patterns, and payer interactions. At the same time, surgical interventions continue to evolve with less invasive techniques and refined perioperative care, maintaining their role where clinical severity and comorbidity profiles necessitate durable anatomical interventions.

Healthcare providers, pharmaceutical developers, device manufacturers, and payers must reconcile these clinical advances with persistent challenges: inconsistent access across demographic groups, fragmented reimbursement frameworks, and pressures on supply chains for active pharmaceutical ingredients and delivery devices. Innovations in digital health, remote monitoring, and patient engagement platforms are beginning to close gaps in follow-up care and behavioral intervention, yet they require integration into existing care ecosystems to deliver measurable outcomes. Consequently, stakeholders who align clinical evidence generation with pragmatic access strategies and cross-disciplinary partnerships will be best positioned to influence both patient outcomes and organizational performance.

This introduction frames the subsequent analysis by emphasizing the interconnected drivers of change-clinical efficacy, delivery modality, regulatory pathways, and commercial strategy-and sets expectations for decision-makers seeking pragmatic, evidence-based guidance. The narrative that follows dissects transformative forces in the field, regulatory and trade headwinds, segmentation-level implications for product and service design, and actionable recommendations to navigate near-term disruption while building long-term resilience.

Evolving clinical paradigms, delivery modalities, and payer expectations are driving a systemic shift from episodic intervention toward longitudinal integrated care models for obesity treatment

The obesity treatment landscape is undergoing transformative shifts driven by breakthroughs in pharmacotherapy, refinements in surgical practice, and the maturation of digital therapeutics. In pharmacology, therapies that harness metabolic and appetite-regulating pathways have demonstrated clinically relevant weight reductions tied to broader cardiometabolic benefits, prompting clinicians and payers to reevaluate lines of therapy and treatment sequencing. This shift is accelerating multidisciplinary care models that integrate endocrinology, primary care, behavioral health, and nutrition services, creating more touchpoints for sustained patient management.

At the same time, procedural innovation in bariatric and minimally invasive surgery has improved perioperative safety and recovery timelines, preserving the role of surgical options for patients with advanced disease or refractory responses to medical therapy. Delivery modalities are also diversifying: oral formulations and parenteral administration coexist, and each route creates distinct adherence, storage, and patient support needs. Parallel to clinical advances, distribution channels are evolving. Retail and specialty clinic models are adapting to omnichannel patient journeys where in-person consultations, telemedicine follow-ups, and e-commerce fulfillment must be coordinated to ensure continuity of care.

Policy and payer landscapes are adapting unevenly, with some payers expanding coverage for pharmacologic therapies contingent on demonstrable outcomes, while others maintain restrictive criteria. This differential access amplifies disparities and incentivizes manufacturers to develop robust real-world evidence and value-based contracting approaches. Overall, the sector is shifting from episodic interventions toward longitudinal management frameworks that blend clinical innovation with systems thinking, emphasizing sustained outcomes, patient experience, and economic value.

Projected trade policy adjustments in 2025 will create compounding operational, pricing, and access implications that necessitate proactive supply chain resilience and reimbursement engagement strategies

The introduction of additional tariffs or trade policy changes in the United States in 2025 introduces a set of cumulative effects that stakeholders across the obesity treatment ecosystem must evaluate and mitigate. Tariffs on imported active pharmaceutical ingredients, delivery devices, or specialized medical equipment would increase input costs for manufacturers that rely on global supply chains. Those cost pressures are likely to cascade through distribution channels, influencing list prices, rebate strategies, and negotiation dynamics with payers and healthcare providers. The magnitude of price transmission will vary depending on contracting structures and the competitive intensity within therapeutic categories.

Beyond immediate cost impacts, tariffs can alter supplier behavior and investment timelines. Suppliers may reshore production, diversify sourcing, or invest in higher inventory buffers to reduce exposure to trade policy volatility. Such strategic moves require capital and time and may lead to short- to medium-term supply inflection points as capacity is reallocated. For parenteral therapies and single-use delivery devices, where sterility and regulatory approvals constrain supplier interchangeability, any disruption can have outsized effects on availability and clinical operations. Facilities that perform bariatric procedures may face increased equipment and implant costs that influence procedural economics and case selection criteria.

Tariff-driven cost increases also have implications for research and development prioritization. Companies may need to reassess pipeline investments or prioritize projects with lower dependency on at-risk imports. At the payer and provider level, increased costs could intensify scrutiny around comparative effectiveness and long-term outcomes, accelerating demand for real-world evidence and health economic analyses. In public health terms, policies that reduce affordability or access could exacerbate existing disparities, disproportionately affecting populations with limited healthcare access or higher baseline prevalence of obesity. Consequently, comprehensive mitigation strategies-including sourcing diversification, collaborative contracting with payers, investment in domestic manufacturing where feasible, and proactive stakeholder communication-are essential to preserve continuity of care and maintain momentum in therapeutic adoption.

A multi-dimensional segmentation perspective connecting treatment modalities, pharmacologic classes, administration routes, patient cohorts, channels, and care settings to strategic imperatives

Segmentation analysis reveals the complex interplay among treatment modalities, pharmacologic mechanisms, administration routes, patient demographics, distribution channels, and end-user settings, each of which carries distinct implications for clinical practice and commercial strategy. Based on treatment type, the landscape includes pharmacotherapy and surgical procedures; pharmacotherapy further divides into over-the-counter drugs and prescription medications, while surgical procedures encompass bariatric surgery, gastric bypass, and laparoscopic surgery. These distinctions matter because each pathway involves different clinical decision points, regulatory requirements, and patient education needs, and they determine the types of stakeholders involved in patient journeys from initial consultation through long-term follow-up.

Based on drug class, therapeutic approaches span appetite suppressants, GLP-1 receptor agonists, lipase inhibitors, and metabolism boosters, each presenting unique efficacy, safety, and monitoring profiles that inform both prescriber behavior and payer criteria. Based on route of administration, the market includes oral and parenteral options; oral therapies offer convenience and potentially broader uptake, while parenteral agents may deliver higher efficacy or different tolerability characteristics and will require administration support and cold-chain logistics. Based on patient age group, stakeholders must address the different clinical needs and adherence challenges of adults, elderly patients, and pediatric populations, paying particular attention to dosing, comorbidity profiles, and long-term follow-up strategies.

Based on distribution channel, treatment access occurs through offline retail and online retail models; offline settings continue to play a critical role for procedural interventions and in-person clinical management, while online channels expand access for certain pharmacologic therapies and ongoing patient support. Based on end-user, services and products are delivered across hospitals and clinics, specialty clinics, and weight loss and wellness centers, each with distinct procurement practices, clinical workflows, and reimbursement environments. Integrating these segmentation lenses reveals where product design, channel strategy, and evidence generation must align to meet clinical needs and payer expectations across diverse patient cohorts and care settings.

Distinct regional regulatory, reimbursement, and cultural dynamics across the Americas, Europe Middle East Africa, and Asia Pacific require tailored access and evidence strategies

Regional dynamics vary significantly and require differentiated approaches to regulatory engagement, access strategy, and partnership development. In the Americas, regulatory pathways in North America leverage robust clinical trial infrastructure and more mature payer frameworks, producing rapid adoption cycles for high-efficacy therapies where reimbursement aligns with demonstrated outcomes. Health systems in the region are also contending with substantial unmet need and demographic heterogeneity, which creates opportunities for integrated care models and value-based contracting that tie reimbursement to sustained clinical benefit.

In Europe, the Middle East & Africa, regulatory regimes present a patchwork of approval timelines and reimbursement criteria that necessitate targeted market entry planning and local evidence generation. Several countries prioritize cost-effectiveness and comparative analyses within health technology assessment frameworks, driving the need for region-specific real-world data and economic models. In many emerging markets across these regions, infrastructure constraints and out-of-pocket payment prevalence affect the feasible adoption pathways for both pharmacologic and surgical interventions.

In the Asia-Pacific region, market heterogeneity includes advanced markets with sophisticated regulatory systems alongside rapidly developing health systems where rising prevalence and growing middle-class demand are increasing access to obesity treatments. Supply chain considerations, local manufacturing capacities, and regional regulatory harmonization efforts influence launch sequencing and commercial investments. Across all regions, cultural perceptions of obesity, provider training, and the availability of multidisciplinary care teams shape adoption curves and long-term treatment paradigms, making localized stakeholder engagement and tailored evidence packages essential for successful program implementation.

Competitive advantage will accrue to organizations that combine differentiated clinical outcomes evidence, integrated care partnerships, and adaptable commercial and supply chain capabilities

Competitive dynamics are increasingly defined by the ability to demonstrate differentiated clinical outcomes, optimize delivery and support services, and engage payers with persuasive health economic evidence. Leading biopharmaceutical developers are investing in outcome studies and patient support programs to address adherence, persistence, and long-term safety monitoring, while device and procedural innovators emphasize improved perioperative pathways and enhanced recovery protocols to reduce complications and total episode costs. Partnerships between drug developers and specialty clinics or digital health providers are emerging as a way to integrate behavioral interventions, remote monitoring, and adherence support into commercial offerings, increasing the perceived value for payers and patients alike.

Strategic capabilities that separate successful organizations from peers include robust real-world evidence generation, flexible manufacturing and supply chain arrangements, and sophisticated payer engagement models that can support value-based reimbursement. Companies that invest in education for clinicians and allied health professionals, while simultaneously scaling patient engagement tools, stand to accelerate adoption and improve outcomes. Additionally, cross-sector collaboration-spanning pharmaceuticals, device manufacturers, health systems, and technology providers-creates opportunities to deliver end-to-end solutions that address both the biological and behavioral components of obesity, positioning organizations to capture more of the continuum of care.

Practical and coordinated actions for leaders to fortify supply chains, build value-based evidence, and expand integrated patient delivery models to safeguard access and accelerate adoption

Industry leaders should pursue a coordinated set of actions that align clinical evidence generation, supply chain resilience, and payer engagement to preserve access and sustain innovation. First, diversify sourcing and invest in regional manufacturing or strategic supplier partnerships to mitigate exposure to trade policy disruptions and to reduce lead-time risk for critical inputs such as active pharmaceutical ingredients and single-use devices. Complement supply-side measures with inventory optimization and contractual clauses that allow for flexibility during periods of geopolitical uncertainty.

Second, prioritize the generation of rigorous real-world evidence and health economic models that demonstrate long-term value across relevant patient populations and care settings. Use pragmatic trials, registries, and payer data partnerships to quantify outcomes that matter to payers, including reductions in comorbidity burden, hospital utilization, and total cost of care. Third, innovate in patient support and delivery models: integrate digital therapeutics, remote monitoring, and multidisciplinary care coordination to improve adherence and persistence, while reducing the burden on brick-and-mortar facilities.

Fourth, engage proactively with payers and health technology assessment bodies to design reimbursement pathways that reflect longitudinal benefits rather than short-term cost metrics. Consider pilots for outcomes-based contracts that align pricing to sustained clinical endpoints. Fifth, tailor regional market entry and commercialization strategies to local regulatory requirements, cultural contexts, and infrastructure realities, using local partnerships to expedite uptake. Finally, invest in workforce development by equipping clinicians, nurses, and allied health professionals with the training and tools needed to deliver complex chronic-disease management effectively. Together, these actions will strengthen organizational resilience and help sustain patient access during periods of disruption.

A layered research methodology blending primary stakeholder interviews, targeted secondary intelligence, and rigorous triangulation to ensure actionable and defensible insights

The research approach combines a layered methodology designed to triangulate insights from diverse and credible sources. The primary research component includes structured interviews with clinicians, payers, procurement leaders, and patient advocacy representatives to capture firsthand perspectives on clinical decision-making, reimbursement constraints, and access barriers. Supplementing these interviews, expert advisory panels provide thematic validation and scenario testing to stress-test strategic assumptions and to surface emerging operational risks.

Secondary research draws on peer-reviewed clinical literature, regulatory filings, public policy documents, and published guidance from relevant health authorities to construct the clinical and regulatory context. Commercial intelligence is gathered from company disclosures, trial registries, and patent landscapes to map competitive positioning and innovation trajectories. Where appropriate, real-world datasets and claims analyses are used to assess utilization patterns and care pathways, while methodological safeguards-such as data cleaning, outlier analysis, and triangulation-ensure analytical rigor.

Analytical techniques include thematic synthesis for qualitative inputs, comparative regulatory analysis, and health economic modeling frameworks to interpret cost and outcome relationships qualitatively. Limitations of the methodology are acknowledged: stakeholder perspectives may evolve rapidly with new clinical data or policy changes, and access to certain proprietary datasets can constrain granularity. To mitigate these limitations, iterative updates and targeted follow-up interviews are recommended following major regulatory or clinical developments.

A concise synthesis emphasizing the strategic imperative to combine clinical evidence, operational resilience, and payer engagement to enhance outcomes and sustain access

The obesity treatment ecosystem is at an inflection point where clinical innovation, supply chain realities, and payer expectations converge to redefine care pathways. Stakeholders that proactively align evidence generation with pragmatic access strategies and resilient operational planning will capture disproportionate value while improving patient outcomes. The interplay between pharmacologic advances and procedural care underscores the need for integrated, multidisciplinary approaches that account for patient heterogeneity and long-term management needs.

Managing near-term risks-such as trade policy shifts, supply chain constraints, and reimbursement variability-requires deliberate actions that include sourcing diversification, targeted real-world evidence development, and close payer collaboration. Simultaneously, investments in digital care models and patient support mechanisms can enhance adherence and extend the benefits of clinical advances to broader patient populations. In sum, the path forward favors organizations that balance scientific rigor with operational agility and who partner across the care continuum to deliver measurable, sustainable improvements in patient health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obesity Treatment Market, by Treatment Type

  • 8.1. Pharmacotherapy
    • 8.1.1. Over-The-Counter Drugs
    • 8.1.2. Prescription Medications
  • 8.2. Surgical Procedures
    • 8.2.1. Bariatric Surgery
    • 8.2.2. Gastric Bypass
    • 8.2.3. Laparoscopic Surgery

9. Obesity Treatment Market, by Drug Class

  • 9.1. Appetite Suppressants
  • 9.2. GLP-1 Receptor Agonists
  • 9.3. Lipase Inhibitors
  • 9.4. Metabolism Boosters

10. Obesity Treatment Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Obesity Treatment Market, by Patient Age Group

  • 11.1. Adults
  • 11.2. Elderly
  • 11.3. Pediatric

12. Obesity Treatment Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Obesity Treatment Market, by End-User

  • 13.1. Hospitals & Clinics
  • 13.2. Specialty Clinics
  • 13.3. Weight Loss & Wellness Centers

14. Obesity Treatment Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obesity Treatment Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obesity Treatment Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Obesity Treatment Market

18. China Obesity Treatment Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Apollo Endosurgery, Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Atkins Nutritionals, Inc.
  • 19.9. BTL Aesthetics
  • 19.10. C.H. Boehringer Sohn AG & Ko. KG
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. GlaxoSmithKline plc.
  • 19.14. Herbalife Ltd.
  • 19.15. Johnson & Johnson Services, Inc.
  • 19.16. Kellogg Company
  • 19.17. Medtronic PLC
  • 19.18. Merck & Co.
  • 19.19. Novo Nordisk A/S
  • 19.20. NutriSystem, Inc.
  • 19.21. Olympus Corporation
  • 19.22. Pfizer, Inc.
  • 19.23. ReShape Lifesciences, Inc.
  • 19.24. Rhythm Pharmaceuticals, Inc.
  • 19.25. Sanofi SA
  • 19.26. Takeda Pharmaceutical Company Limited
  • 19.27. Viking Therapeutics, Inc.
  • 19.28. VIVUS LLC
  • 19.29. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBESITY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBESITY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PRESCRIPTION MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBESITY TREATMENT MARKET SIZE, BY BARIATRIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBESITY TREATMENT MARKET SIZE, BY APPETITE SUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBESITY TREATMENT MARKET SIZE, BY LIPASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBESITY TREATMENT MARKET SIZE, BY METABOLISM BOOSTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBESITY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBESITY TREATMENT MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBESITY TREATMENT MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBESITY TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBESITY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBESITY TREATMENT MARKET SIZE, BY WEIGHT LOSS & WELLNESS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBESITY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL OBESITY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 160. GCC OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GCC OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 187. G7 OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. G7 OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 196. NATO OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. NATO OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL OBESITY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA OBESITY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA OBESITY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA OBESITY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA OBESITY TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA OBESITY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA OBESITY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA OBESITY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA OBESITY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA OBESITY TREATMENT MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)